UniSa - IRIS Institutional Research Information System

MASARONE, Mario
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 8.778
NA - Nord America 5.361
EU - Europa 1.689
SA - Sud America 785
AF - Africa 125
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 5
Totale 16.749
Salva come PNG Salva come JPEG
Nazione #
HK - Hong Kong 5.755
US - Stati Uniti d'America 5.228
SG - Singapore 1.304
CN - Cina 640
BR - Brasile 602
VN - Vietnam 475
IT - Italia 389
RU - Federazione Russa 281
UA - Ucraina 191
DE - Germania 168
FR - Francia 150
TR - Turchia 130
IE - Irlanda 126
KR - Corea 110
GB - Regno Unito 79
AR - Argentina 77
SE - Svezia 73
FI - Finlandia 65
CA - Canada 64
IN - India 62
BD - Bangladesh 58
MX - Messico 43
ZA - Sudafrica 43
JP - Giappone 37
IQ - Iraq 36
EC - Ecuador 33
ID - Indonesia 33
NL - Olanda 31
DK - Danimarca 26
PL - Polonia 22
VE - Venezuela 22
CO - Colombia 20
PK - Pakistan 20
ES - Italia 18
AT - Austria 17
UZ - Uzbekistan 15
MA - Marocco 14
SA - Arabia Saudita 13
CZ - Repubblica Ceca 12
PY - Paraguay 12
EG - Egitto 11
AE - Emirati Arabi Uniti 10
MY - Malesia 9
PS - Palestinian Territory 9
KE - Kenya 8
PH - Filippine 8
AL - Albania 7
KZ - Kazakistan 7
LT - Lituania 7
TN - Tunisia 7
AZ - Azerbaigian 6
DZ - Algeria 6
HN - Honduras 6
PE - Perù 6
SN - Senegal 6
EU - Europa 5
RO - Romania 5
AU - Australia 4
CG - Congo 4
CL - Cile 4
CR - Costa Rica 4
DO - Repubblica Dominicana 4
GR - Grecia 4
IL - Israele 4
JM - Giamaica 4
JO - Giordania 4
OM - Oman 4
UG - Uganda 4
AO - Angola 3
BH - Bahrain 3
BN - Brunei Darussalam 3
BO - Bolivia 3
CI - Costa d'Avorio 3
ET - Etiopia 3
LY - Libia 3
NO - Norvegia 3
NP - Nepal 3
QA - Qatar 3
UY - Uruguay 3
CH - Svizzera 2
GE - Georgia 2
GT - Guatemala 2
GY - Guiana 2
IR - Iran 2
LB - Libano 2
LV - Lettonia 2
MW - Malawi 2
PT - Portogallo 2
RS - Serbia 2
TH - Thailandia 2
TW - Taiwan 2
AF - Afghanistan, Repubblica islamica di 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BJ - Benin 1
BS - Bahamas 1
BW - Botswana 1
BY - Bielorussia 1
CY - Cipro 1
GA - Gabon 1
Totale 16.727
Salva come PNG Salva come JPEG
Città #
Hong Kong 5.745
Ann Arbor 778
San Jose 647
Singapore 634
Chandler 360
Princeton 344
Ashburn 335
Woodbridge 334
Jacksonville 263
Dallas 244
Houston 177
Beijing 161
Council Bluffs 141
The Dalles 140
Dublin 123
Ho Chi Minh City 123
Lauterbourg 108
Dong Ket 106
Izmir 106
Wilmington 102
Hanoi 87
Moscow 74
Nanjing 73
Los Angeles 69
Andover 63
New York 62
São Paulo 58
Munich 56
Naples 45
Boardman 44
Pellezzano 44
Santa Clara 38
Tokyo 35
Fairfield 27
Salerno 27
Johannesburg 26
Redwood City 26
Changsha 24
Hebei 23
Montreal 23
Norwalk 23
Frankfurt am Main 22
Shenyang 22
Turku 22
Columbus 21
Haiphong 21
Rio de Janeiro 20
Washington 20
Orem 19
Warsaw 19
Amsterdam 18
Brooklyn 18
Chennai 18
Mexico City 18
Stockholm 18
Belo Horizonte 17
Da Nang 17
Denver 17
Jinan 17
Nanchang 17
Dearborn 16
Dhaka 16
London 16
Tashkent 15
Atlanta 14
Jiaxing 14
Milan 14
Nuremberg 14
Phoenix 14
Seattle 13
Baghdad 12
Brasília 12
Chicago 12
Curitiba 12
Guayaquil 12
Helsinki 12
Tianjin 12
Copenhagen 11
Guangzhou 11
Caracas 10
Fisciano 10
Jinju 10
Manchester 10
Nürnberg 10
Poplar 10
Boston 9
City of London 9
Erbil 9
Maletto 9
Ninh Bình 9
Ottawa 9
Pontecagnano 9
San Diego 9
Ankara 8
Biên Hòa 8
Cambridge 8
Haikou 8
Rome 8
Seoul 8
Toronto 8
Totale 12.719
Salva come PNG Salva come JPEG
Nome #
Characterisation of asymptomatic patients and efficacy of preventive measures for SARS-CoV-2 infection in a large population of Southern Italy: a cohort study 759
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 758
Non Alcoholic Fatty Liver: Epidemiology and Natural History 620
Impact of telaprevir in HCV patients with cirrhosis and RVR: Real-life data from boceprevir or telaprevir based “triple therapy” experience in southern Italy 599
Pressure support ventilation vs Continuous positive airway pressure for treating of acute cardiogenic pulmonary edema: A pilot study 493
Overview of prognostic systems for hepatocellular carcinoma and ITA.LI.CA external validation of MESH and CNLC classifications 432
Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL Study 381
Hepatitis C virus infection in jail: Difficult-to-reach, not to-treat. Results of a point-of-care screening and treatment program 369
Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma. 341
Liver biopsy in type 2 diabetes mellitus: Steatohepatitis represents the sole feature of liver damage 320
The influence of acute lifestyle changes on NAFLD evolution in a multicentre cohort: a matter of body composition 312
442 TNF-alpha and IL-10 genetic polymorphisms influence the natural history and the response to antiviral therapy in HCV related chronic hepatitis 310
Alcoholic Hepatitis: Pathogenesis, Diagnosis and Treatment 297
Predicting de-novo portal vein thrombosis after HCV eradication: A long-term competing risk analysis in the ongoing PITER cohort 279
"Non alcoholic fatty liver disease and eNOS dysfunction in humans" 263
VIROLOGICAL PATTERNS OF HCV PATIENTS WITH FAILURE TO INTERFERON-FREE REGIMENS 207
Efficacy and safety of new direct antiviral agents in HCV infected patients with Diffuse Large B Cell Non-Hodgkin Lymphoma 202
Sustained virological response by direct antiviral agents in HCV leads to an early and significant improvement of liver fibrosis 190
The diagnostic conundrum in non-alcoholic fatty liver disease 188
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 186
A Long-term Treatment with Silybin in Patients with Non-alcoholic Steatohepatitis Stimulates Catalase Activity in Human Endothelial Cells 177
Diaphragmatic motility assessment in COPD exacerbation, early detection of Non-Invasive Mechanical Ventilation failure: a pilot study 154
Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3 150
HIGH PREVALENCE OF HEPATITIS C (HCV) INFECTION AND FAVORABLE PROGNOSIS IN PRIMARY HEPATIC LYMPHOMA (PHL) 149
Association between non-alcoholic fatty liver disease, insulin resistance and Helicobacter pylori. 148
[629] THE INFLUENCE OF OBESITY AND DIABETES ON CLINICAL AND THERAPEUTICAL OUTCOME IN HCV RELATED CHRONIC HEPATITIS: AN ITALIAN NATIONWIDE SURVEY STUDY (PROBE GROUP) 147
Coeliac disease and C virus-related chronic hepatitis: a non association 147
Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis 143
Endocan Serum Levels in Patients with Non-Alcoholic Fatty Liver Disease with or without Type 2 Diabetes Mellitus: A Pilot Study 142
Pharmacotherapy of alcoholic liver disease in clinical practice 136
Alcoholic Liver Disease and Hepatitis C Chronic Infection 136
Epidemiology and Natural History of Alcoholic Liver Disease 135
Adiponectin in hepatology 134
507 The role of HBV occult infection in patients with non-hodgkin lymphoma: Prevalence and treatment options with nucleotide analogues 131
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 130
Antiviral therapy: Why does it fail in HCV-related chronic hepatitis? 128
The effect of antiviral therapy on hepatitis C virus-related thrombocytopenia: a case report. 123
Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease 123
Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma. 120
The role of fructose in non-alcoholic steatohepatitis: Old relationship and new insights 120
Screening, Linkage to Care and Treatment of Hepatitis C Infection in Primary Care Setting in the South of Italy 119
Lispro insulin in people with non-alcoholic liver cirrhosis and type 2 diabetes mellitus 118
Chemical effect of bisphenol a on non-alcoholic fatty liver disease 118
Vascular endothelial dysfunction in inflammatory bowel diseases: Pharmacological and nonpharmacological targets 116
Occult hepatitis B virus infection in patients with non-Hodgkin lymphoma: the need for early diagnosis in anti-Hbc positive patients 115
Helicobacter pylori infection but not small intestinal bacterial overgrowth may play a pathogenic role in rosacea 115
Real-life effectiveness and safety of Glecaprevir/Pibrentasvir in HCV infected patients with chronic kidney disease 114
Corrigendum to "Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma" [J Hepatol 49 (2008) 557-563] (DOI:10.1016/j.jhep.2008.06.025) 112
Genetic predictors of response to treatment of chronic hepatitis C virus infection in patients from southern Italy 110
Lactate determination in pleural and abdominal effusions: a quick diagnostic marker of exudate-a pilot study 108
HCV antiviral therapy in injection drug users: difficult to treat or easy to cure? 106
Lung ultrasound for diagnosis of pneumonia in emergency department 105
Chitosan-coated liposomes loaded with butyric acid demonstrate anticancer and anti-inflammatory activity in human hepatoma HepG2 cells 105
Impact of telaprevir in HCV patients with cirrhosis and RVR: real-life data from Boceprevir or Telaprevir based "triple therapy" experience in southern Italy 104
Etiology of newly-diagnosed cases of chronic liver disease in Southern Italy: Results of a prospective multicentric study 104
Viral hepatitis: Milestones, unresolved issues, and future goals 103
Evaluation of allelic frequency and genetic risk score of non-alcoholic fatty liver disease in a population of Southern Italy 103
Assessing the impact of COVID-19 on the management of patients with liver diseases: A national survey by the Italian association for the study of the Liver 102
The epidemiology of non-alcoholic fatty liver disease and its connection with cardiovascular disease: Role of endothelial dysfunction 101
Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease 101
Hepatitis C virus carriers with persistently normal ALT levels: biological peculiarities and update of the natural history of liver disease at 10 years. 100
Hepatitis C screening during SARS-CoV-2 testing or vaccination. Experience in an area of Southern Italy in the province of Salerno 100
The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. 99
Steatohepatitis is associated with diabetes and fibrosis in genotype 1b HCV-related chronic liver disease 99
Inferior vena cava collapsibility to guide fluid removal in slow continuous ultrafiltration: A pilot study 99
Interference of diet on liver histology and on the response to interferon therapy in patients with HCV-related chronic liver disease 98
Alcoholic Consumption of Young Italians During the SARS-CoV-2 Pandemic 94
Qualitative and Quantitative Evaluation of Dietary Intake in Patients with Non-Alcoholic Steatohepatitis 94
HCV-genotype 3h, a difficult-to-diagnose sub-genotype in the DAA era 94
FN 44 HEPATIC RETINOL BINDING PROTEIN 4 (RBP-4) LEVELS ARE SIGNIFICANTLY RELATED TO THE STEATOHEPATITIS GRADE (COMPROMISSION) BUT NOT WITH HCV INFECTION 93
Real‐Life Efficacy and Safety of Glecaprevir/Pibrentasvir in HCV Infected Patients with Chronic Kidney Disease 93
Erratum to: HBV and HCV infection in type 2 diabetes mellitus: a survey in three diabetes units in different Italian areas 92
Role of bisphenol A as environmental factor in the promotion of non-alcoholic fatty liver disease: in vitro and clinical study 92
Clinical expression of insulin resistance in hepatitis C and B virus-related chronic hepatitis: differences and similarities. 91
Metabolic associated steatotic liver disease in renal transplant recipients: a retrospective cohort study 90
Rapid Virological Response Represents the Highest Prediction Factor of Response to Antiviral Treatment in HCV-Related Chronic Hepatitis: a Multicenter Retrospective Study. 88
A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease 87
P. 253 Rapid virological response in genotype 1b patients treated with peginterferon plus ribavirin: evidence for a significant sustained virological response (SVR) after 24 weeks of therapy in peg-interferon-alpha-2a treated patients 87
HBV and HCV infection in type 2 diabetes mellitus: a survey in three diabetes units in different Italian areas 87
Associated screening for HCV and SARS-Cov2 infection in an urban area of Southern Italy: a cohort study 87
Inflammation and Fibrogenesis in MAFLD: Role of the Hepatic Immune System 87
Interleukin-10 - 1082 GG polymorphism influences the occurrence and the clinical characteristics of hepatitis C virus infection. 85
Hepatitis C Virus Infection and Non-Hepatocellular Malignancies in the DAA Era: A Systematic Review and Meta-Analysis 84
HCV point-of-care screening program and treatment options for people who use drugs in a metropolitan area of Southern Italy 84
NAFLD and extra-hepatic comorbidities: Current evidence on a multi-organ metabolic syndrome 83
Gut-Liver Axis Dysregulation in Portal Hypertension: Emerging Frontiers 82
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network 82
Evaluating cardiovascular risk in metabolic steatosis with precision medicine non-invasive approaches: insights from a cohort study 81
The impact of diet on liver fibrosis and on response to interferon therapy in patients with HCV-related chronic hepatitis. 79
Corrigendum to “Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)” [Dig Liver Dis 54 (2022) 170–182, (S1590865821002140), (10.1016/j.dld.2021.04.029)] 78
Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters, and Serological Worsening Markers in Nonalcoholic Fatty Liver Disease Patients 78
A prospective study of DAA Effectiveness and Relapse Risk in HCV Cryoglobulinemic Vasculitis by the Italian PITER Cohort 74
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 73
Indirect markers of non-alcoholic fatty liver disease: Another piece of the puzzle? 72
Solving the gap between HCV detection and treatment in prison. HCV-RNA testing and treatment in a cohort of new arriving convicts in Southern Italy 70
From Non-Alcoholic Steatohepatitis (NASH) to Hepatocellular Carcinoma (HCC): Epidemiology, Incidence, Predictions, Risk Factors, and Prevention 68
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort 66
Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function 65
The role of resveratrol in liver disease: A comprehensive review from in vitro to clinical trials 64
Country-Wide HCV Elimination Strategies Need to Reach Older Patients in the General Population: The Italian Experience 63
Totale 15.840
Salva come PNG Salva come JPEG
Categoria #
all - tutte 53.289
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 53.289
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021211 0 0 0 0 0 0 0 0 0 0 81 130
2021/2022609 6 6 9 7 10 10 22 31 83 82 80 263
2022/2023918 102 72 54 110 99 189 3 67 135 5 60 22
2023/2024515 35 49 36 24 39 100 26 31 9 19 35 112
2024/20251.585 32 29 23 53 106 165 272 150 284 106 189 176
2025/202610.402 695 2.891 2.923 522 776 366 927 219 392 606 85 0
Totale 17.016